Cocrystal Pharma names interim CEO
This article was originally published in Scrip
Executive Summary
Dr Gary Wilcox has stepped down as CEO of Cocrystal Pharma – a company focused on developing novel antiviral therapeutics for human diseases – due to medical reasons. As a result, Jeffrey Meckler has been appointed interim CEO of the company. Dr Wilcox will become the vice-chair of Cocrystal's board of directors and will continue as a senior advisor to the company. Mr Meckler will continue as a director of the company, and Dr Raymond F Schinazi will become the chair of the board.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.